BioPharmSignal logoBioPharmSignal

Biotech News

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

ALX Oncology (ALXO)ALX OncologyClinical readout

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 trial in HER2-positive gastric cancer, which indicated CD47 expression could

Related news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

KURAKura Oncology2026-06-11 12:02 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

COGTCogent Biosciences2026-06-12 12:00 EST

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

COGTCogent Biosciences2026-06-30 12:00 EST

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

IDYAIDEAYA Biosciences2026-06-15 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

LYELLyell Immunopharma2026-06-08 10:00 EST

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

View all latest news

ALX Oncology

CD47-Directed Immuno-Oncology ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells. Evorpacept Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other...

Recent company news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALXOALX Oncology2026-06-30 20:40 EST

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALXOALX Oncology2026-06-30 12:00 EST

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALXOALX Oncology2026-06-01 12:00 EST

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

ALXOALX Oncology2026-05-08 12:00 EST

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
2.04 USD
Market cap
239.52M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States